Table 2.
The miRNA expression levels (mean ± SD) in the AML sub-groups with weak/constant ABO antigen expression and in the control group.
| AML |
Control |
|||
|---|---|---|---|---|
| Weak (N = 7) | Constant (N = 12) | All (N = 19) | (N = 12) | |
| miR155 | 1.39 ± 1.17 | 1.98 ± 1.28 | 1.76 ± 1.24 | 1.46 ± 1.33 |
| miR150 | 0.65 ± 0.45 | 0.77 ± 0.58 | 0.73 ± 0.52 | 1.07 ± 0.40 |
| miR221 | 1.60 ± 1.41 | 1.58 ± 0.97 | 1.59 ± 1.11 | 1.31 ± 0.94 |
| miR222 | 1.66 ± 1.57 | 1.49 ± 1.09 | 1.55 ± 1.24 | 1.26 ± 0.92 |
| miR223 | 1.49 ± 1.68 | 1.44 ± 1.03 | 1.46 ± 1.26 | 1.39 ± 1.19 |
| miR95p | 2.59 ± 3.63 | 2.66 ± 5.17 | 2.64 ± 4.55 | 1.28 ± 1.01 |
| miR2033P | 3.93 ± 6.58 | 3.06 ± 4.58 | 3.38 ± 5.24 | 1.48 ± 1.37 |
| miR5745P | 3.83 ± 6.95 | 2.23 ± 2.76 | 2.82 ± 4.63 | 1.36 ± 1.14 |
| miR8485P | 4.25 ± 7.37 | 3.71 ± 7.21 | 3.91 ± 7.07 | 1.32 ± 0.98 |
| miR3313P | 3.78 ± 5.99 | 3.22 ± 4.99 | 3.43 ± 5.22 | 1.27 ± 0.97 |
| miR19085P | 1.26 ± 0.71 | 1.88 ± 3.17 | 1.65 ± 2.53 | 1.09 ± 0.48 |
| miR1 | 2.12 ± 1.44 | 3.15 ± 6.17 | 2.77 ± 4.92 | 1.55 ± 1.45 |
| miR10a | 1.39 ± 0.97 | 1.97 ± 3.12 | 1.76 ± 2.52 | 1.14 ± 0.58 |
| miR24 | 0.66 ± 0.39 | 1.45 ± 3.38 | 1.16 ± 2.68 | 2.67 ± 3.88 |
| miR125b | 1.48 ± 1.75 | 2.20 ± 1.55 | 1.94 ± 1.62 | 1.58 ± 1.71 |
| miR145 | 1.11 ± 0.74 | 0.82 ± 0.56 | 0.92 ± 0.63 | 1.17 ± 0.63 |
| miR16 | 0.31 ± 0.24a | 0.61 ± 0.74a | 0.50 ± 0.62a | 1.29 ± 1.01b |
| miR451 | 0.46 ± 0.32a | 0.57 ± 0.49a | 0.53 ± 0.43a | 1.39 ± 1.21b |
a
The Mann–Whitney U test compared with the control group had p＜ 0.05.
b
The Kruskal–Wallis test among the control group, the AML group with weak ABO antigen expressions and the AML group with constant ABO antigen expressions had p＜ 0.05.